Sotera Health Company Common Stock (SHC)
Stock · NASDAQ · Health Care
$17.9as of 10/16/2026
Price chart
Active signals
SHC Signal Track Record
How signals performed across all stocks →What SHC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -2.8% | 41% | September 16, 2026 |
| Bollinger Band Breakdown | 26 | -0.3% | 50% | June 2, 2026 |
| Bollinger Band Breakout | 24 | +2.4% | 71% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -4.8% | 27% | June 10, 2026 |
| Any 20-session window (baseline) | -0.4% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SHC
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron bea…
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- Employees
- 3,000
- Website
- soterahealth.com/
Fundamentals
- 1-day range
- $17.79$18.51
- Market cap
- $5.39B
- P/E (trailing)
- 31.54
- P/E (forward)
- 16.64
- EPS (trailing)
- $0.57
- Dividend yield
- —
- Beta
- 1.93
- Avg. volume
- 2.43M
How Sotera Health Company Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Sotera Health Company Common Stock Competitors
Chosen by industry and closest market cap.
- SHCSotera Health Company Common Stock$17.89▼ 1.00%Market cap $5.39BP/E 31.54$13.09$19.85
- PGNYProgyny Inc. Common Stock$26.86▼ 2.17%Market cap $2.37BP/E 25.32$16.1$33.07
- AGLagilon health inc. Common Stock$85.12▼ 3.76%Market cap $1.45BP/E —$7.48$133.04
- VMDViemed Healthcare Inc. Common Shares$9.48▼ 2.77%Market cap $362.60MP/E 25.72$6.05$12.61
- PARKPark Dental Partners Inc. Common Stock$18.95▼ 1.33%Market cap $96.71MP/E —$9.53$26.79
- CCELCryo-Cell International Inc. Common Stock$4.42▲ 21.10%Market cap $28.78MP/E —$2.72$4.9
- MGRXMangoceuticals Inc. Common Stock$0.29▼ 9.66%Market cap $10.31MP/E —$0.162$2.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SHC Sotera Health Company Common Stock | $5.39B | 31.54 | $17.89 | ▼ 1.00% | $13.09$19.85 |
| PGNY Progyny Inc. Common Stock | $2.37B | 25.32 | $26.86 | ▼ 2.17% | $16.1$33.07 |
| AGL agilon health inc. Common Stock | $1.45B | — | $85.12 | ▼ 3.76% | $7.48$133.04 |
| VMD Viemed Healthcare Inc. Common Shares | $362.60M | 25.72 | $9.48 | ▼ 2.77% | $6.05$12.61 |
| PARK Park Dental Partners Inc. Common Stock | $96.71M | — | $18.95 | ▼ 1.33% | $9.53$26.79 |
| CCEL Cryo-Cell International Inc. Common Stock | $28.78M | — | $4.42 | ▲ 21.10% | $2.72$4.9 |
| MGRX Mangoceuticals Inc. Common Stock | $10.31M | — | $0.29 | ▼ 9.66% | $0.162$2.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Downgrades Sotera Health to Underweight, Announces $17 Price Targetbenzinga · 10/14/2026
- Is Sotera Health (SHC) Still A Bargain After A 35% Gain?Yahoo · 10/9/2026
- Transcript: Sotera Health Q2 2026 Earnings Conference CallBenzinga · 10/9/2026
- Sotera Health: Pricing Power And Recurring Revenues Are Growth DriversSeekingAlpha · 9/18/2026
- Here’s Why Sotera Health Company (SHC) Surges 25% in Q2Yahoo · 9/15/2026
- 3 of Wall Street’s Favorite Stocks We Approach with CautionYahoo · 9/14/2026
Insider Activity
Insider Actions →- Petras Michael B. Jr. · August 17, 2026 · Sale294.5K @ $18.5
- Petras Michael B. Jr. · August 17, 2026 · Sale850.0K @ $18.5
- Rutz Michael P · August 7, 2026 · Sale150.0K @ $18.84
- Lyons Jonathan M. · August 5, 2026 · Tax Withholding11.3K @ $17.98
- SHADER ALTON · May 26, 2026 · Grant101.8K
- SHADER ALTON · May 26, 2026 · Grant203.6K
- SHADER ALTON · May 26, 2026 · Grant375.9K
- Karen Flynn · May 22, 2026 · Grant15.0K
- Kyle Richard G · May 22, 2026 · Grant15.0K
- Neary James · May 22, 2026 · Grant15.0K
- Vincent K. Petrella · May 22, 2026 · Grant15.0K
- CUNNINGHAM SEAN LAURENCE · May 22, 2026 · Grant15.0K
- Klee Ann R. · May 22, 2026 · Grant15.0K
- David E. Wheadon · May 22, 2026 · Grant15.0K
- Chen Ruoxi · May 22, 2026 · Grant15.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 262.69M
- Total value held
- $3.58B
- Institutional holders
- 286
- Unknown26.00M
- Unknown23.05M
- Unknown21.72M
- Unknown20.85M
- Unknown19.10M
- Unknown12.74M
- Unknown11.64M
- Unknown10.74M
- Unknown9.16M
- Unknown9.13M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.